IONS - Ionis Pharmaceuticals, Inc.
After hours:
Chart Events
Commodity Channel Index
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 43.33 |
| Open | 40.49 |
| Bid | 40.56 x 1400 |
| Ask | 41.55 x 1800 |
| Day's Range | 40.24 - 41.59 |
| 52 Week Range | 32.69 - 48.82 |
| Volume | |
| Avg. Volume | 1,021,271 |
| Market Cap | 5.802B |
| Beta (5Y Monthly) | 0.54 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.37 |
| Earnings Date | Aug 07, 2023 - Aug 11, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 48.11 |
Fair Value
Related Research
TheStreet.comI've Got My Eye On Ionis Pharmaceuticals for Higher Highs
Ionis Pharmaceuticals, Inc. IONS is a biotechnology company that specializes in discovering and developing RNA-targeted therapeutics. In the daily bar chart of IONS, below, I can see that the shares have broken their downward path and launched an uptrend. The On-Balance-Volume (OBV) line has risen from the middle of March, telling me that buyers of IONS have been more aggressive than sellers.
PR NewswireIonis announces proposed private placement of convertible notes
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it intends to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of Convertible Senior Notes due 2028 (the "notes") in a private placement (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Ionis also intends to grant the initial purchasers of the notes an option to purchase, within the 13-day peri
ZacksIonis Pharmaceuticals (IONS) Up 19.3% Since Last Earnings Report: Can It Continue?
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- PR Newswire
Ionis announces positive donidalorsen late-stage clinical progress in HAE
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive clinical progress with donidalorsen, its late-stage investigational prophylactic therapy for hereditary angioedema (HAE). Topline two-year open-label extension (OLE) results continue to demonstrate consistent efficacy and safety, with an overall sustained mean reduction in HAE attack rates of 96% from baseline through two years across dosing groups. The company also announced that it has completed enrollment in the Phase 3 OASIS
Investor's Business DailyIonis Pharmaceuticals Stock Sees IBD RS Rating Climb To 79
Ionis Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating
- PR Newswire
Ionis to host 2023 virtual Annual Meeting of Stockholders
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2023 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 1, 2023.
- PR Newswire
Ionis to present at upcoming investor conferences
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:
ZacksIonis (IONS) Q1 Earnings Surpass Estimates, Sales Match
Ionis (IONS) reports a narrower-than-expected Q1 loss. Sales come in line with estimates. The company re-affirms its previously issued financial guidance for 2023.
- Thomson Reuters StreetEvents
Q1 2023 Ionis Pharmaceuticals Inc Earnings Call
Q1 2023 Ionis Pharmaceuticals Inc Earnings Call
ZacksHere's What Key Metrics Tell Us About Ionis Pharmaceuticals (IONS) Q1 Earnings
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ZacksIonis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 13% and 0.30%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Ionis reports first quarter 2023 financial results
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company"), today reported financial results for the first quarter of 2023. Financial results are summarized below:
ZacksAvalo Therapeutics, Inc. (AVTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Avalo Therapeutics, Inc. (AVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksEarnings Preview: Ionis Pharmaceuticals (IONS) Q1 Earnings Expected to Decline
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire
FDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALS
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner Biogen has received U.S. Food and Drug Administration (FDA) approval of QALSODY™ (tofersen) 100 mg/15mL injection for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. This indication is approved under accelerated approval based on a reduction in plasma neurofilament light chain (NfL) observed in patients treated with QALSODY. Continued approval
InvestorPlace3 Biotech Stocks to Sell Before They’re 6 Feet Under
In a high-interest-rate environment, cash is king. All biotech companies will need to continue spending to finance their R&D. But debt-fueled spending is becoming expensive. And selling stock will just dilute current shareholders. All companies will find it hard to deal with this, but none more so than companies with negative earnings and little cash on hand. While some companies can delay the inevitable for a surprisingly long time, gravity is likely to catch up to unprofitable companies eventu
- PR Newswire
Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the Phase 3 NEURO-TTRansform study for AstraZeneca and Ionis' eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) met all co-primary endpoints and secondary endpoints at 66 weeks versus an external placebo group. The positive results are being presented today in an Emerging Science Session at the American Academy of Neurology (AAN) 2023 Annual Meeting in Boston. ATTRv-PN is a debilitating
- PR Newswire
Ionis to hold first quarter 2023 financial results webcast
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, May 3rd at 11:30 a.m. Eastern Time to discuss its first quarter 2023 financial results.
Motley FoolCould This Rare-Disease Drug Candidate Become a Blockbuster?
This drug candidate could be a great treatment option for patients with a potentially deadly disease.
- PR Newswire
New data presented at AD/PD™2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer's disease
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported that its partner Biogen presented new Phase 1b clinical data showing that IONIS-MAPTRx (BIIB080) reduced soluble tau protein in cerebrospinal fluid (CSF) in a dose-dependent and sustained manner in patients with early-stage Alzheimer's disease (AD). IONIS-MAPTRx also reduced aggregated tau pathology, as measured by positron emission tomography (PET) in all brain composites assessed. The primary endpoint of the Phase 1b study (25 weeks) an
BenzingaAstraZeneca-Ionis Partnered Rare Disease Drug Data Shows Sustained Benefit; Drug Under FDA Review
Ionis Pharmaceuticals Inc (NASDAQ: IONS) released topline results from the 66-week analysis of Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca Plc's (NASDAQ: AZN) eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) that leads to peripheral nerve damage and motor disability. At 66 weeks, patients treated with eplontersen demonstrated a statistically significant and clinically meaningful change from baseline versus an external placebo group on t
ZacksIonis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study
Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
- PR Newswire
Ionis reports positive topline 66-week results of eplontersen Phase 3 study for patients with ATTRv-PN
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the 66-week analysis of the Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca's eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN), a debilitating and potentially fatal disease that leads to peripheral nerve damage and motor disability.
ZacksWhy Is Ionis Pharmaceuticals (IONS) Down 8.4% Since Last Earnings Report?
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Investor's Business DailyBiogen Pops — But Ionis Hands Back Gains — After ALS Drug Wins A Key Endorsement
Biogen stock jumped — as Ionis stock gave back early gains — after a FDA panel offered a mixed view of their ALS treatment.